赛诺菲喜保宁有哪些副作用？

(Vigabatrin tablets) are currently used in clinical practice for the treatment of infantile spasms (IS) and refractory complex partial-onset epilepsy (CPS). The benefit-risk ratios for IS and CPS are different. In terms of efficacy, vigabatrin is currently the only drug approved by regulatory authorities in various countries for the treatment of IS, and its efficacy is accurate. However, if this disease is not treated, the prognosis is very poor, and there is a serious risk of disability or even death. For CPS, there are currently relatively many treatment drugs to choose from. Vigabatrin can be used as a second-line or third-line drug when other drugs are ineffective. Moreover, according to the research results, the effect of vigabatrin on CPS is not as significant as that on IS.

In terms of safety, the incidence of visual field narrowing caused by vigabatrin is relatively low in infants and children, and the anti-epileptic drugs already used by CPS patients may further increase the risk of visual field narrowing. Therefore, the benefit-risk ratio of Vigabatrin for IS patients is generally higher than that for CPS patients. As far as the current situation in my country is concerned, vigabatrin has been listed as an urgent clinical drug for IS, and its benefits and risks for patients with refractory CPS need to be further evaluated based on the current status of epilepsy diagnosis and treatment in my country and the accessibility of ophthalmic visual field examination technology.

Some scholars suggest that before applying vigabatrin for treatment, a detailed assessment of possible benefits and complications is needed. However, some scholars have put forward different opinions: Because the symptoms of visual field defects discovered so far are mostly mild and rarely affect the lives of children, too much emphasis on visual field defects will affect the early drug treatment of such children. During specific treatment, it is necessary to formulate a reasonable treatment plan based on the actual situation of the patient.

Sanofi is a world-leading diversified pharmaceutical and health company. Its business covers vaccines, prescription drugs, health pharmaceutical products and animal health products. It has more than 100,000 employees and operates in more than 100 countries. Although Sanofi has certain side effects, its overall efficacy is obvious and patients can use it with confidence.

Recommended hot articles: /newsDetail/93748.html